RESUMO
A series of fused 6,6-bicyclic chromenones was investigated for activity against the bradykinin B1 receptor. SAR studies based on a pharmacophore model revealed compounds with high affinity for both human and rabbit B1. These compounds demonstrated favorable pharmacokinetic properties and 5-chlorochromenone 15 was efficacious in a carrageenan-induced mechanical hyperalgesia model for chronic pain.
Assuntos
Benzopiranos/síntese química , Antagonistas de Receptor B1 da Bradicinina , Animais , Benzopiranos/farmacologia , Carragenina/farmacologia , Química Farmacêutica/métodos , Dor Crônica/tratamento farmacológico , Desenho de Fármacos , Humanos , Hiperalgesia/tratamento farmacológico , Concentração Inibidora 50 , Cinética , Modelos Químicos , Coelhos , Relação Estrutura-Atividade , Fator de Necrose Tumoral alfa/metabolismoRESUMO
The discovery of novel and highly potent oxopiperazine based B1 receptor antagonists is described. Compared to the previously described arylsulfonylated (R)-3-amino-3-phenylpropionic acid series, the current compounds showed improved in vitro potency and metabolic stability. Compound 17, 2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-2-piperazinyl)-N-((1R)-6-(1-piperidinylmethyl)-1,2,3,4-tetrahydro-1-naphthalenyl)acetamide, showed EC(50) of 10.3 nM in a rabbit biochemical challenge model. The practical syntheses of chiral arylsulfonylated oxopiperazine acetic acids are also described.
Assuntos
Acetamidas/uso terapêutico , Antagonistas de Receptor B1 da Bradicinina , Inflamação/tratamento farmacológico , Dor/tratamento farmacológico , Piperazinas/uso terapêutico , Acetamidas/síntese química , Acetamidas/química , Animais , Cães , Concentração Inibidora 50 , Camundongos , Modelos Animais , Estrutura Molecular , Piperazinas/síntese química , Piperazinas/química , Coelhos , Ratos , Receptor B1 da Bradicinina/química , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
We report the development of aryl sulfones as Bradykinin B1 receptor antagonists. Variation of the linker region identified diol 23 as a potent B1 antagonist, while modifications of the aryl moiety led to compound 26, both of which were efficacious in rabbit biochemical challenge and pain models.
Assuntos
Antagonistas de Receptor B1 da Bradicinina , Dor/tratamento farmacológico , Sulfonas/farmacologia , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/farmacologia , Antagonistas de Receptor B2 da Bradicinina , Doença Crônica , Humanos , Coelhos , Ratos , Ratos Sprague-Dawley , Sulfonas/administração & dosagemRESUMO
Inhibition of the PHD2 enzyme has been associated with increased red blood cell levels. From a screening hit, a series of novel hydroxyl-thiazoles were developed as potent PHD2 inhibitors.
Assuntos
Subunidade alfa do Fator 1 Induzível por Hipóxia/síntese química , Tiazóis/química , Química Farmacêutica/métodos , Diabetes Mellitus/tratamento farmacológico , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos/métodos , Eritrócitos/enzimologia , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/química , Concentração Inibidora 50 , Modelos Químicos , Modelos Moleculares , Infarto do Miocárdio/tratamento farmacológico , Doenças Vasculares Periféricas/terapia , Acidente Vascular Cerebral/tratamento farmacológico , Relação Estrutura-Atividade , Tiazóis/farmacologiaRESUMO
The bradykinin B1 receptor is rapidly induced upon tissue injury and inflammation, stimulating the production of inflammatory mediators resulting in plasma extravasation, leukocyte trafficking, edema, and pain. We have previously reported on sulfonamide and sulfone-based B1 antagonists containing a privileged bicyclic amine moiety leading to potent series of 2-oxopiperazines. The suboptimal pharmacokinetics and physicochemical properties of the oxopiperazine sulfonamides led us to seek B1 antagonists with improved druglike properties. Using a pharmacophore model containing a bicyclic amine as anchor, we designed a series of amide antagonists with targeted physicochemical properties. This approach led to a novel series of potent phthalazinone B1 antagonists, where we successfully replaced a sulfonamide acceptor with a cyclic carbonyl unit. SAR studies revealed compounds with subnanomolar B1 binding affinity. These compounds demonstrate excellent cross-species PK properties with high oral bioavailability and potent activity in a rabbit biochemical challenge pharmacodynamic study.